{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:17:59Z","timestamp":1792120679526,"version":"4.4.0"},"reference-count":37,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors. Metastases develop in 15% to 20%. The American Joint Committee on Cancer (AJCC) established inaugural guidelines for PPGL tumor-node-metastasis (TNM) staging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this analysis is to investigate the associations between TNM staging and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively applied the TNM staging at the time of diagnosis of the primary tumor. The primary outcome was OS. Unadjusted survival rates were estimated by the Kaplan\u2013Meier method. Cox proportional hazards regression models were used to evaluate the associations between OS and covariates of interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 458 patients. Median OS was 18.0 (95% CI, 15.6-not reached) years. At diagnosis, 126 (27.5%) tumors were stage I, 213 (46.5%) were stage II, 47 (10.3%) were stage III, and 72 (15.7%) were stage IV. The 10-year OS probabilities were 0.844 (95% CI, 0.768-0.928) for patients with stage I tumors, 0.792 (95% CI, 0.726-0.865) for stage II, 0.595 (95% CI, 0.435-0.813) for stage III, and 0.221 (95% CI, 0.127-0.384) for stage IV. Compared with stage I, the hazard ratios (HR) for death were 1.50 (0.87-2.57) for stage II, 2.85 (1.45-5.63) for stage III, and 8.88 (5.16-15.29) for stage IV (P &amp;lt; 0.001). Compared with patients with no germline mutations, those with RET 634\/918 had better OS (HR: 0.28; 95% CI, 0.12-0.69). Other germline mutations, including SDHB, did not exhibit worse OS than patients with metastasis and sporadic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>OS rates correlated with the recently developed AJCC TNM staging and were not worse in hereditary disease. Stage IV disease exhibited a significantly shorter OS compared with stages I-III. Future staging systems could be adjusted to better separate stages I and II.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgac677","type":"journal-article","created":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T07:29:51Z","timestamp":1669447791000},"page":"1132-1142","source":"Crossref","is-referenced-by-count":35,"title":["TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5292-3355","authenticated-orcid":false,"given":"Camilo","family":"Jimenez","sequence":"first","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsheng","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5942-1035","authenticated-orcid":false,"given":"Alejandro","family":"Roman Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"},{"name":"Department of Endocrinology, San Vicente Fundaci\u00f3n-Universidad de Antioquia , Medellin , Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeena","family":"Varghese","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Perrier","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouhammed Amir","family":"Habra","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Graham","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-0100","authenticated-orcid":false,"given":"Steven G","family":"Waguespack","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,11,26]]},"reference":[{"issue":"3","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol"},{"issue":"4","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American Neuroendocrine Tumor Society Consensus Guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"issue":"2","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"101354","DOI":"10.1016\/j.beem.2019.101354","article-title":"Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies","volume":"34","author":"Jasim","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fendo.2018.00277","article-title":"Treatment for patients with malignant pheochromocytomas and paragangliomas: a perspective from the hallmarks of cancer","volume":"9","author":"Jimenez","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2012-4231","article-title":"Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma","volume":"98","author":"Ayala-Ramirez","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","article-title":"Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma","volume":"15","author":"Jimenez","year":"2013","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1210\/jc.2013-1907","article-title":"One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma","volume":"98","author":"Hescot","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-017-0643-0","article-title":"Treatment for malignant pheochromocytomas and paragangliomas: 5 years of progress","volume":"19","author":"Jimenez","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MED.0000000000000330","article-title":"Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials","volume":"24","author":"Roman-Gonzalez","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2023041309385409600_","first-page":"919","volume-title":"AJCC Cancer Staging Manual","author":"Jimenez","year":"2017","edition":"8"},{"key":"2023041309385409600_","volume-title":"WHO classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs","author":"Lloyd","edition":"4"},{"key":"2023041309385409600_","volume-title":"AJCC Cancer Staging Manual","author":"Amin","edition":"8"},{"issue":"2","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1245\/s10434-017-6074-1","article-title":"Clinical predictors of malignancy in patients with pheochromocytoma and paraganglioma","volume":"24","author":"Dhir","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"762548","DOI":"10.3389\/fendo.2021.762548","article-title":"Local-regional recurrence of pheochromocytoma\/paraganglioma: characteristics, risk factors and outcomes","volume":"12","author":"Cui","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2023041309385409600_","volume-title":"WHO Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs","author":"DeLellis","edition":"3"},{"issue":"6","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12020-015-0672-0","article-title":"Functional imaging for pheochromocytoma-paraganglioma: a step closer to understanding its place in clinical practice","volume":"50","author":"Jimenez","year":"2015","journal-title":"Endocrine"},{"issue":"1","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/CCO.0000000000000249","article-title":"Pheochromocytoma and paraganglioma: molecular testing and personalized medicine","volume":"28","author":"Burnichon","year":"2016","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr Rev"},{"issue":"10","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Ta\u00efeb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"684668","DOI":"10.3389\/fendo.2021.684668","article-title":"Prognostic nomograms for predicting overall survival and cancer-specific survival of patients with malignant pheochromocytoma and paraganglioma","volume":"12","author":"Zheng","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12020-021-02854-3","article-title":"Assessment of the AJCC staging system of pheochromocytomas\/paragangliomas","volume":"75","author":"Abdel-Rahman","year":"2022","journal-title":"Endocrine"},{"issue":"1","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Ann Surg"},{"issue":"9","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1210\/clinem\/dgab202","article-title":"Recurrence-free survival analysis in locally advanced pheochromocytoma: first appraisal","volume":"106","author":"Moog","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/SLA.0000000000002671","article-title":"Preoperative 18F-FDG PET\/CT in pheochromocytomas and paragangliomas allows for precision surgery","volume":"269","author":"Nockel","year":"2019","journal-title":"Ann Surg"},{"issue":"5","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/cancers11071018","article-title":"Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine","volume":"11","author":"Jimenez","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"issue":"11","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"E1813","DOI":"10.1210\/jc.2013-1653","article-title":"The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2","volume":"98","author":"Thosani","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono study): an ENS@T retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1210\/jc.2005-2178","article-title":"Review: should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?","volume":"91","author":"Jim\u00e9nez","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S2213-8587(20)30314-4","article-title":"Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study","volume":"8","author":"Ebbehoj","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2023041309385409600_","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.surg.2019.04.030","article-title":"Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up","volume":"166","author":"Stenman","year":"2019","journal-title":"Surgery"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac677\/47750462\/dgac677.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/5\/1132\/49873758\/dgac677.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/5\/1132\/49873758\/dgac677.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T16:52:44Z","timestamp":1701449564000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/5\/1132\/6847640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,26]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11,26]]},"published-print":{"date-parts":[[2023,4,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac677","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,11,26]]}}}